FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151471516> ?p ?o ?g. }

• W2151471516 endingPage "414" @default.
• W2151471516 startingPage "404" @default.
• W2151471516 abstract "background and Objective The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P450 (CYP) 2C8 and CYP3A4 in vitro. Our objective was to study the effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone to determine the role of these enzymes in the fate of pioglitazone in humans. Methods In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itraconazole (first dose, 200 mg), both gemfibrozil and itraconazole, or placebo twice daily for 4 days. On day 3, they received a single dose of 15 mg pioglitazone. Plasma drug concentrations and the cumulative excretion of pioglitazone and its metabolites into urine were measured for up to 48 hours. Results Gemfibrozil alone raised the mean total area under the plasma concentration-time curve from time 0 to infinity [AUC(0-∞)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P < .001) and prolonged its elimination half-life (t½) from 8.3 to 22.7 hours (P < .001) but had no significant effect on its peak concentration (Cmax) compared with placebo (control). Gemfibrozil increased the 48-hour excretion of pioglitazone into urine by 2.5-fold (P < .001) and reduced the ratios of the active metabolites M-III and M-IV to pioglitazone in plasma and urine. Gemfibrozil decreased the area under the plasma concentration-time curve from time 0 to 48 hours [AUC(0–48)] of the metabolites M-III and M-IV by 42% (P < .05) and 45% (P < .001), respectively, but their total AUC(0-∞) values were reduced by less or not at all. Itraconazole had no significant effect on the pharmacokinetics of pioglitazone and did not alter the effect of gemfibrozil on pioglitazone pharmacokinetics. The mean area under the concentration versus time curve to 49 hours [AUC(0–49)] of itraconazole was 46% lower (P < .001) during the gemfibrozil-itraconazole phase than during the itraconazole phase. Conclusions Gemfibrozil elevates the plasma concentrations of pioglitazone, probably by inhibition of its CYP2C8-mediated metabolism. CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metabolism in vivo in humans. Concomitant use of gemfibrozil with pioglitazone may increase the effects and risk of dose-related adverse effects of pioglitazone. However, studies in diabetic patients are needed to determine the clinical significance of the gemfibrozil-pioglitazone interaction. Clinical Pharmacology & Therapeutics (2005) 77, 404–414; doi: 10.1016/j.clpt.2004.12.266" @default.
• W2151471516 created "2016-06-24" @default.
• W2151471516 creator A5022004406 @default.
• W2151471516 creator A5075309527 @default.
• W2151471516 creator A5083054649 @default.
• W2151471516 creator A5089475081 @default.
• W2151471516 date "2005-05-01" @default.
• W2151471516 modified "2023-10-16" @default.
• W2151471516 title "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone" @default.
• W2151471516 cites W1558276030 @default.
• W2151471516 cites W1934270266 @default.
• W2151471516 cites W1978530024 @default.
• W2151471516 cites W1979820286 @default.
• W2151471516 cites W1983687170 @default.
• W2151471516 cites W1984636592 @default.
• W2151471516 cites W1993536574 @default.
• W2151471516 cites W2004576165 @default.
• W2151471516 cites W2010241890 @default.
• W2151471516 cites W2012793432 @default.
• W2151471516 cites W2015279471 @default.
• W2151471516 cites W2017573139 @default.
• W2151471516 cites W2032094362 @default.
• W2151471516 cites W2054040800 @default.
• W2151471516 cites W2063680021 @default.
• W2151471516 cites W2070098436 @default.
• W2151471516 cites W2087015670 @default.
• W2151471516 cites W2100744461 @default.
• W2151471516 cites W2158607621 @default.
• W2151471516 cites W2159234101 @default.
• W2151471516 cites W2163711771 @default.
• W2151471516 cites W2164739027 @default.
• W2151471516 cites W2411660655 @default.
• W2151471516 cites W2417796581 @default.
• W2151471516 doi "https://doi.org/10.1016/j.clpt.2004.12.266" @default.
• W2151471516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15900286" @default.
• W2151471516 hasPublicationYear "2005" @default.
• W2151471516 type Work @default.
• W2151471516 sameAs 2151471516 @default.
• W2151471516 citedByCount "105" @default.
• W2151471516 countsByYear W21514715162012 @default.
• W2151471516 countsByYear W21514715162013 @default.
• W2151471516 countsByYear W21514715162014 @default.
• W2151471516 countsByYear W21514715162015 @default.
• W2151471516 countsByYear W21514715162016 @default.
• W2151471516 countsByYear W21514715162017 @default.
• W2151471516 countsByYear W21514715162018 @default.
• W2151471516 countsByYear W21514715162019 @default.
• W2151471516 countsByYear W21514715162020 @default.
• W2151471516 countsByYear W21514715162021 @default.
• W2151471516 countsByYear W21514715162022 @default.
• W2151471516 countsByYear W21514715162023 @default.
• W2151471516 crossrefType "journal-article" @default.
• W2151471516 hasAuthorship W2151471516A5022004406 @default.
• W2151471516 hasAuthorship W2151471516A5075309527 @default.
• W2151471516 hasAuthorship W2151471516A5083054649 @default.
• W2151471516 hasAuthorship W2151471516A5089475081 @default.
• W2151471516 hasConcept C10146269 @default.
• W2151471516 hasConcept C112705442 @default.
• W2151471516 hasConcept C126322002 @default.
• W2151471516 hasConcept C134018914 @default.
• W2151471516 hasConcept C142724271 @default.
• W2151471516 hasConcept C185592680 @default.
• W2151471516 hasConcept C204787440 @default.
• W2151471516 hasConcept C22979827 @default.
• W2151471516 hasConcept C27081682 @default.
• W2151471516 hasConcept C2776923340 @default.
• W2151471516 hasConcept C2777180221 @default.
• W2151471516 hasConcept C2778163477 @default.
• W2151471516 hasConcept C2778384471 @default.
• W2151471516 hasConcept C2778670441 @default.
• W2151471516 hasConcept C2780026642 @default.
• W2151471516 hasConcept C555293320 @default.
• W2151471516 hasConcept C71924100 @default.
• W2151471516 hasConcept C87813604 @default.
• W2151471516 hasConcept C98274493 @default.
• W2151471516 hasConceptScore W2151471516C10146269 @default.
• W2151471516 hasConceptScore W2151471516C112705442 @default.
• W2151471516 hasConceptScore W2151471516C126322002 @default.
• W2151471516 hasConceptScore W2151471516C134018914 @default.
• W2151471516 hasConceptScore W2151471516C142724271 @default.
• W2151471516 hasConceptScore W2151471516C185592680 @default.
• W2151471516 hasConceptScore W2151471516C204787440 @default.
• W2151471516 hasConceptScore W2151471516C22979827 @default.
• W2151471516 hasConceptScore W2151471516C27081682 @default.
• W2151471516 hasConceptScore W2151471516C2776923340 @default.
• W2151471516 hasConceptScore W2151471516C2777180221 @default.
• W2151471516 hasConceptScore W2151471516C2778163477 @default.
• W2151471516 hasConceptScore W2151471516C2778384471 @default.
• W2151471516 hasConceptScore W2151471516C2778670441 @default.
• W2151471516 hasConceptScore W2151471516C2780026642 @default.
• W2151471516 hasConceptScore W2151471516C555293320 @default.
• W2151471516 hasConceptScore W2151471516C71924100 @default.
• W2151471516 hasConceptScore W2151471516C87813604 @default.
• W2151471516 hasConceptScore W2151471516C98274493 @default.
• W2151471516 hasIssue "5" @default.
• W2151471516 hasLocation W21514715161 @default.
• W2151471516 hasLocation W21514715162 @default.
• W2151471516 hasOpenAccess W2151471516 @default.

• next